• First patient enrolled in cohort combining bexobrutideg with venetoclax
  • Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL
  • Strategy includes evaluation of bexobrutideg given in combination with venetoclax and selected antibodies in the Roche portfolio of B-cell malignancy therapies